Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) -Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.
The collaboration will help Bristol Myers to expand its manufacturing capacity due to increasing demand. The company said in February it was looking to launch both its CAR-T blood cancer therapies Abecma and Breyanzi in a number of new countries this year.
CAR-T therapy involves removing a patients' own T cells - a key component of the immune system - engineering them to recognize and attack malignant cells, and re-infusing them.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)
